QualityDipStocks / Health Care · Pharmaceuticals
Hutchmed HCM
Outside our quality screen, so we don’t track its dips. It’s 17% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Net cash = 54% of its market cap
- ROE 46% and more cash than debt
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- —
- Off 52-wk high
- −17%
- Risk vs market
- Below marketbeta 0.75
4 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for HCM: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much HCM moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, but its own price swings are 3.0× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.75
- Volatility
- 39% vs 13% SPY
- Correlation SPY
- 0.25
- Correlation QQQ
- 0.18
How it ranks
Where HCM stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 4 measures
- Free cash flow yield−3.4% · free cash flow vs market capLowest 10%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months−13% · vs the 12 months beforeLowest 2%of 1,814
- Operating margin−7.1% · of sales kept as operating profitLowest 7%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ValuationP/E of 5.0× vs a 29.0× median for the 135 Health Care companies we cover.
Balance sheetNet cash of $1.2B: cash and short-term investments exceed debt (Dec 31, 2025).
ProfitabilityReturn on equity of 46% over the last 12 months, up 23 points in two years.
Balance sheetDebt / equity of 0.1×, below the 0.6× median for the 126 Health Care companies we cover.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$79M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityGross margin narrowed to 38.7% in FY2025 from 54.1% in FY2023 (SEC filings).
Balance sheetOperating income covers interest only -13.7× over the last 12 months.
ProfitabilityOperating margin narrowed to −7.1% in FY2025 from 2.2% in FY2023 (SEC filings).
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%.
All fundamentals
P/E 5.0 · FCF yield -3.4% · ROE 46%
Valuation
- P/E
- 5.0×Health Care median 29.0×
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −3.4%
- EV / EBITDA
- n/anegative EBITDA
- Price / sales
- n/aneeds total revenue: the SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- Price / book
- 1.86×
- Market cap
- $2.3Blisted
- Enterprise value
- $1.1B
Growth
- Revenue, 12 months
- n/athe SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- Sales growth, 12 months
- n/aneeds total revenue: the SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- Sales growth, 3 yrs
- n/aneeds total revenue: the SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- Diluted EPS, 12 months
- $0.52
- EPS growth, last FY
- n/an/m: EPS a year ago near zero
- Net income, 12 months
- $457M
- Net income growth
- n/an/m: earnings a year ago near zero
Profitability
- Gross margin
- 38.7%
- Operating margin
- −7.1%
- Net margin
- n/aneeds total revenue: the SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- FCF margin
- −14.4%
- Return on equity
- 46%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $1.4B
- Total debt
- $118M
- Net cash
- $1.2B
- Debt / equity
- 0.10×
- Interest coverage
- -13.7×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- −$79M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Dec 31, 2025; balance sheet at Dec 31, 2025. From Hutchmed’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.0B · Sales 0%
- Free cash flow, 12 months−$0.0B
- Free-cash-flow yield-3.4%
- Free-cash-flow margin−3%
- Gross margin13%
- Operating margin0%
- Return on equity2%
- Sales growth (latest quarter vs year-ago quarter)0%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $13.27
- 52-wk lowlowest close, 1 year$9.99−24.7%
- PriceMon Nov 2 close$13.27you are here
- 52-wk highhighest close, 1 year$16.05+20.9%
Momentum & 52-week range
RSI 43 · 5 days −7.0%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
HCM is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Hutchmed in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.